| Members |
targetComponentId |
| Amphetamine/dextroamphetamine 10mg prolonged-release oral capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 15mg m/r capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 15mg prolonged-release oral capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 20mg m/r capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 20mg prolonged-release oral capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 25mg m/r capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 25mg prolonged-release oral capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 30mg m/r capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 30mg prolonged-release oral capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 5mg m/r capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphetamine/dextroamphetamine 5mg prolonged-release oral capsule |
Product containing only amfetamine and dexamfetamine (medicinal product) |
| Amphotericin (lipid formulation) 5mg/mL suspension for injection 10mL vial |
Amphotericin B liposome 5 mg/mL solution for injection |
| Amphotericin 5mg/mL infusion concentrate 10mL vial |
Amphotericin B liposome 5 mg/mL solution for injection |
| Amphotericin b 50mg infusion solution vial |
Amphotericin B 50 mg powder for solution for injection vial |
| Amphotericin b 50mg injection |
Amphotericin B 50 mg powder for solution for injection vial |
| Amphotericin b 50mg powder for infusion solution vial |
Amphotericin B 50 mg powder for solution for injection vial |
| Amphotericin b 50mg/vial powder |
Amphotericin B 50 mg powder for solution for injection vial |
| Amphotericin b 5mg/mL infusion solution vial |
Product containing precisely amphotericin B lipid complex 5 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Ampicillin + flucloxacillin 125mg/125mg/5mL elixir |
Product containing precisely ampicillin 25 milligram/1 milliliter and flucloxacillin (as flucloxacillin magnesium) 25 milligram/1 milliliter conventional release oral suspension (clinical drug) |
| Ampicilloyl extract |
Product containing ampicillin (medicinal product) |
| Ampulla of Vater TNM finding |
American Joint Committee on Cancer allowable value |
| Amputation of arm NOS |
Amputation of upper limb (procedure) |
| Amputation of arm NOS |
Amputation of upper limb (procedure) |
| Amputation of leg NOS |
Amputation of lower limb (procedure) |
| Amputation of leg NOS |
Amputation of lower limb (procedure) |
| Amputation of thigh through femur |
Amputation above-knee |
| Amyl nitrate - non-pharmaceutical |
Amyl nitrate |
| Amylase + lipase + protease 12000unt/4000unt/12000unt capsule |
Product containing precisely amylase 12000 unit and endopeptidase 12000 unit and triacylglycerol lipase 4000 unit/1 each gastro-resistant oral capsule (clinical drug) |
| Amylase + lipase + protease 16600unt/5000unt/18750unt capsule |
Product containing precisely amylase 16600 unit and endopeptidase 18800 unit and triacylglycerol lipase 5000 unit/1 each conventional release oral capsule (clinical drug) |
| Amylase + lipase + protease 20000unt/4500unt/25000unt capsule |
Product containing precisely amylase 20000 unit and endopeptidase 25000 unit and pancreatic lipase 4500 unit/1 each conventional release oral capsule (clinical drug) |
| Amylase + lipase + protease 20000unt/5000unt/20000unt capsule |
Product containing precisely amylase 20000 unit and endopeptidase 20000 unit and triacylglycerol lipase 5000 unit/1 each conventional release oral capsule (clinical drug) |
| Amylase + lipase + protease 25000unt/4000unt/25000unt capsule |
Amylase 25000 unit and endopeptidase 25000 unit and triacylglycerol lipase 4000 unit oral capsule |
| Amylase + lipase + protease 30000unt/10000unt/30000unt capsule |
Amylase 30000 unit and endopeptidase 30000 unit and triacylglycerol lipase 10000 unit gastro-resistant oral capsule |
| Amylase + lipase + protease 30000unt/8000unt/30000unt capsule |
Amylase 30000 unit and endopeptidase 30000 unit and triacylglycerol lipase 8000 unit oral capsule |
| Amylase + lipase + protease 30000unt/8000unt/30000unt tablet |
Product containing precisely amylase 30000 unit and endopeptidase 30000 unit and triacylglycerol lipase 8000 unit/1 each conventional release oral tablet (clinical drug) |
| Amylase + lipase + protease 3000unt/2400unt/3000unt capsule |
Amylase 3000 unit and endopeptidase 3000 unit and triacylglycerol lipase 2400 unit oral capsule |
| Amylase + lipase + protease 33200unt/10000unt/37500unt capsule |
Amylase 33200 unit and endopeptidase 37500 unit and triacylglycerol lipase 10000 unit gastro-resistant oral capsule |
| Amylase + lipase + protease 39000unt/12000unt/39000unt capsule |
Product containing precisely amylase 39000 unit and endopeptidase 39000 unit and triacylglycerol lipase 12000 unit/1 each conventional release oral capsule (clinical drug) |
| Amylase + lipase + protease 40000unt/8000unt/45000unt capsule |
Product containing precisely amylase 40000 unit and endopeptidase 45000 unit and triacylglycerol lipase 8000 unit/1 each conventional release oral capsule (clinical drug) |
| Amylase + lipase + protease 48000unt/16000unt/48000unt capsule |
Amylase 48000 unit and endopeptidase 48000 unit and triacylglycerol lipase 16000 unit gastro-resistant oral capsule |
| Amylase + lipase + protease 56000unt/20000unt/44000unt capsule |
Amylase 56000 unit and endopeptidase 44000 unit and triacylglycerol lipase 20000 unit oral capsule |
| Amylase + lipase + protease 58500unt/18000unt/58500unt capsule |
Product containing precisely amylase 58500 unit and endopeptidase 58500 unit and triacylglycerol lipase 18000 unit/1 each conventional release oral capsule (clinical drug) |
| Amylase + lipase + protease 6000unt/16000unt/6000unt tablet |
Amylase 6000 unit and endopeptidase 6000 unit and triacylglycerol lipase 16000 unit oral tablet |
| Amylase + lipase + protease 65000unt/20000unt/65000unt capsule |
Amylase 65000 unit and endopeptidase 65000 unit and triacylglycerol lipase 20000 unit oral capsule |
| Amylase + lipase + protease 66400unt/20000unt/75000unt capsule |
Amylase 66400 unit and endopeptidase 75000 unit and triacylglycerol lipase 20000 unit gastro-resistant oral capsule |
| Amylase + lipase + protease 664400unt/20000unt/75000unt capsule |
Amylase 664400 unit and endopeptidase 75000 unit and triacylglycerol lipase 20000 unit gastro-resistant oral capsule |
| Amylase + lipase, pancreatic + protease, pancreatic 12500unt/1000unt/12500unt tablet |
Amylase 12500 unit and endopeptidase 12500 unit and triacylglycerol lipase 1000 unit oral tablet |
| Amylase + lipase, pancreatic + protease, pancreatic 65000unt/20000unt/65000unt capsule |
Amylase 65000 unit and endopeptidase 65000 unit and triacylglycerol lipase 20000 unit oral capsule |
| Amylobarbitone sodium adverse reaction |
Amylobarbitone adverse reaction |
| Amylobarbitone sodium allergy |
Allergy to amobarbital (finding) |
| Amyloidogenic transthyretin amyloidosis |
Wild type ATTR amyloidosis (disorder) |
| Amyoplasia congenita disruptive sequence |
Congenital amyoplasia (disorder) |
| Anaemia unspecified |
Anemia |
| Anaerococcus tretradius |
Anaerococcus tetradius (organism) |
| Anaesthetic or analgesic |
Medicinal product acting as analgesic agent (product) |
| Anaesthetics and medical gases |
Medicinal product acting as anesthetic agent (product) |
| Anakinra 100mg injection solution 0.67mL prefilled syringe |
Product containing precisely anakinra 149 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Anakinra 100mg/0.67mL injection prefilled syringe |
Product containing precisely anakinra 149 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Anakinra 100mg/mL injection solution 1mL prefilled syringe |
Product containing precisely anakinra 149 milligram/1 milliliter conventional release solution for injection (clinical drug) |
| Anal canal TNM finding |
American Joint Committee on Cancer allowable value |
| Anaphylaxis caused by substance |
Anaphylaxis |
| Anaplasma phagocytophila |
Anaplasma phagocytophilum (organism) |
| Anastomosis of organ NOC |
Construction of anastomosis |
| Anastomosis of pancreas |
Anastomosis of pancreatic duct |
| Anastomosis of stomach to duodenum |
Anastomosis of stomach |
| Anatomic pathology procedure or service |
Anatomic pathology procedure |
| Anatomical concepts |
Physical anatomical entity |
| Anatomical concepts |
Physical anatomical entity |
| Anchovy - dietary |
Anchovy (substance) |
| Anderson D'Alonzo fracture type |
Fracture configurations |
| Anderson D'Alonzo type II fracture |
Anderson and D'Alonso type II fracture |
| Anderson D'Alonzo type III fracture |
Anderson and D'Alonso type III fracture |
| Androblastoma, no International Classification of Diseases for Oncology subtype |
Androblastoma of uncertain behavior (morphologic abnormality) |
| Androstanedione |
Androstenedione |
| Androstenolone |
Dehydroepiandrosterone |
| Anemia caused by substance |
Anemia |
| Anemia due to chemical agent |
Anemia |
| Anemia of chronic disorder, NOS |
Anemia |
| Anemia unspecified |
Anemia |
| Anesthesia for injection procedure for lumbar myelography |
Anesthesia for procedure in lumbar region |
| Anesthetic gas |
Gaseous dose form |
| Angina decubitus NOS |
Angina decubitus |
| Angina self management plan |
Angina self management plan |
| Angioblastic meningioma |
Hemangioblastic meningioma |
| Angiocentric T-cell lymphoma |
Extranodal NK/T-cell lymphoma, nasal type |
| Angiocentric T-cell lymphoma |
Extranodal NK/T-cell lymphoma, nasal type |
| Angiocentric T-cell lymphoma |
Natural killer-/T-cell lymphoma, nasal and nasal-type (morphologic abnormality) |
| Angioendotheliomatosis |
Intravascular large B-cell lymphoma (disorder) |
| Angioendotheliomatosis |
Intravascular large B-cell lymphoma (disorder) |
| Angiofibroma, no International Classification of Diseases for Oncology subtype |
Angiofibroma (morphologic abnormality) |
| Angioimmunoblastic lymphadenopathy with dysproteinemia |
Angioimmunoblastic T-cell lymphoma (disorder) |
| Angioplasty - action |
Dilation - action |
| Angiotensin-converting-enzyme inhibitor allergy |
Non-allergic hypersensitivity to angiotensin-converting enzyme inhibitor |
| Angle-closure glaucoma - borderline |
Angle closure glaucoma suspect (disorder) |
| Anhydrohydroxy progesterone preparation |
Product containing ethisterone (medicinal product) |
| Anidulafungin 100mg powder for injection solution vial |
Product containing only anidulafungin (medicinal product) |
| Animal dander mix radioallergosorbent test |
Epidermal and animal protein specific IgE antibody measurement |
| Animal ear washing |
Irrigation of ear |
| Anion |
Electrolyte anion (substance) |
| Anisocytosis of red cells (morphologic abnormality) |
Anisocytosis, red cells (finding) |
| Ankle brachial pressure index management plan |
Ankle brachial pressure index management plan (record artifact) |